Invasive Glioblastoma Cells Acquire Stemness and Increased Akt Activation  by Molina, Jennifer R. et al.
Invasive Glioblastoma Cells
Acquire Stemness and
Increased Akt Activation1,2
JenniferR.Molina*, YuhoHayashi*, CliftonStephens†
and Maria-Magdalena Georgescu*
*Department of Neuro-oncology, The University of Texas
MD Anderson Cancer Center, Houston, TX, USA;
†Department of Veterinary Medicine and Surgery,
The University of Texas MD Anderson Cancer Center,
Houston, TX, USA
Abstract
Glioblastoma multiforme (GBM) is the most frequent and most aggressive brain tumor in adults. The dismal prog-
nosis is due to postsurgery recurrences arising from escaped invasive tumor cells. The signaling pathways acti-
vated in invasive cells are under investigation, and models are currently designed in search for therapeutic targets.
We developed here an in vivo model of human invasive GBM in mouse brain from a GBM cell line with moderate
tumorigenicity that allowed simultaneous primary tumor growth and dispersal of tumor cells in the brain paren-
chyma. This strategy allowed for the first time the isolation and characterization of matched sets of tumor mass
(Core) and invasive (Inv) cells. Both cell populations, but more markedly Inv cells, acquired stem cell markers, neuro-
sphere renewal ability, and resistance to rapamycin-induced apoptosis relative to parental cells. The comparative
phenotypic analysis between Inv and Core cells showed significantly increased tumorigenicity in vivo and increased
invasion with decreased proliferation in vitro for Inv cells. Examination of a large array of signaling pathways revealed
extracellular signal–regulated kinase (Erk) down-modulation and Akt activation in Inv cells and an opposite profile
in Core cells. Akt activation correlated with the increased tumorigenicity, stemness, and invasiveness, whereas
Erk activation correlated with the proliferation of the cells. These results underscore complementary roles of the
Erk and Akt pathways for GBM proliferation and dispersal and raise important implications for a concurrent inhibi-
tory therapy.
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Introduction
Glioblastoma multiforme (GBM) is the most aggressive form of gli-
omas, accounting for approximately 50% of all glial tumor types.
GBMs are astrocytic-type tumors that may arise de novo in more than
90% of cases or secondary to the progression of lower-grade astro-
cytomas in less than 10% of cases [1]. GBMs are refractory to conven-
tional treatment approaches and have a median survival in the range of
12 to 15 months. Three features of this tumor make it resistant to
therapy: the presence of the blood-brain barrier that restricts drug
distribution to the brain, the heterogeneity of the tumor that consists
of cell populations with different drug sensitivities, and the propensity
of the tumor cells to infiltrate the normal brain leading to recurrences
[2]. Overall, the dismal prognosis of GBM patients is attributable
to drug-resistant relapsing foci arising from infiltrating tumor cells
spreading at a distance from the primary tumor core.
The most frequent genetic alteration in primary GBM is the 10q
chromosome deletion in 70% of cases, followed by alterations that ei-
ther deregulate the cell cycle by targeting the Rb and p53 pathways or
boost cell growth by epidermal growth factor receptor (EGFR) ampli-
fication, overexpression or expression of a constitutively active mutant
form [1,3]. EGFR signaling results in the downstream activation of
the extracellular signal–regulated kinase (Erk) and phosphatidylinositol
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3-OH kinase (PI3K)/Akt pathways. An extra layer of activation of
these pathways in GBM occurs through the inactivation of the up-
stream tumor suppressors of the pathways, NF1 and PTEN, respec-
tively [3,4].
Signaling through both Erk and PI3K/Akt has been implicated in
facilitating the GBM cell invasion triggered by cell attachment to ex-
tracellular matrix (ECM) [5]. However, the pathways that lead to en-
hanced invasiveness of GBM cells are not well characterized. It is
important to bear in mind not only that it is the interaction between
the GBM cells and the brain ECM microenvironment that triggers
the invasion of the GBM cells but also that GBM cells secrete ECM
components that could also modify their migration [6,7].
To uncover what pathways are important for the accelerated dis-
persal of the GBM cells into the brain parenchyma, we developed a
model of human invasive GBM cells in the brain parenchyma of im-
munodeficient mice. Isolation and characterization of sets of matched
tumor core cells and invasive cells slowly growing out within the
brain from the same pool of parental cells revealed acquisition of stem
cell properties and complementary proliferation and invasive pheno-
types of the cell populations. Further analysis uncovered a cross talk
between the PI3K and Erk pathways in GBM cells that underlies
the observed phenotypes.
Materials and Methods
Vectors, Transfections, and Infections
293T cells, U251-MG GBM cells, and normal human astrocytes
(NHAs; gift from T.J. Liu) were grown in Dulbecco’s modified Eagle
medium (DMEM) supplemented with 10% FBS. The complemen-
tary DNA for the enhanced green fluorescent protein (GFP) was in-
serted in the pCXp retroviral vector (puromycin selection), and the
complementary DNA for mCherry (gift from Roger Y. Tsien) was in-
serted in the pCXb vector (blasticidin selection). Transfections and ret-
roviral infections were performed as described [8]. U251-MG and
NHAs were infected with GFP- or mCherry-containing retroviruses,
respectively, and subjected to 14 days of drug selection to stably ex-
press the markers.
Orthotopic Intracranial Injections
For intracranial cell implantation of U251-GFP–labeled parental
cells into the right hemisphere at a point situated 2.5 mm anterior
and lateral from the bregma, the implantable guide-screw system was
used on 6-week-old severe combined immunodeficient (SCID) mice
( Jackson Laboratory, Bar Harbor, ME) [9]. A total of 2 × 106 GFP-
labeled U251-MG cells were washed and resuspended in 15 μl of
DMEM containing 0.7 μg/ml Matrigel (BD Biosciences, San Jose,
CA). The mice were anesthetized, and the cell suspension was slowly
injected into the bolt using a Hamilton syringe attached to the PDH
2000 Infusion machine (Harvard Apparatus, Holliston, MA). The
wound was clipped closed, sterilized with Betadine (Purdue Pharma,
Stanford, CT), and mice were followed up for brain tumor devel-
opment. Injections for the tumor mass (Core) and invasive (Inv)
cells were performed similarly by direct intracranial injection of 2 ×
106 cells.
Establishment of the Core and Inv Cell Lines
Once the mice developed strong neurological symptoms because
of brain tumor burden, they were killed in a CO2 chamber, and the
brains were immediately collected and were either fixed in formalin
for pathological analysis or placed into a sterile dish containing PBS
for further dissection and cell collection. Images of the whole brain
with U251-GFP cells in situ were obtained with a fluorescence Zeiss
Axiovert 200M microscope (Carl Zeiss MicroImaging, Thronwood,
NY) before cell collection. The right frontal lobe containing the in-
jection site and the tumor core was dissected from the rest of the
brain containing the invasive tumor cells. Both brain sections were
separately triturated with a scalpel, pelleted, resuspended in 0.25%
trypsin-EDTA, and rotated on a warm plate for 15 minutes. Cells were
centrifuged and resuspended in DMEM, 10% FBS, and 0.5 μg/ml
puromycin to ensure purity of the culture. The Inv and Core cells
were isolated and constantly grown on Matrigel (0.7 mg/ml)-coated
dishes. In these conditions, they maintained their differential prolifer-
ation phenotype for at least 6 to 10 passages in culture. Freshly isolated
cells were expanded in culture for two passages taking approximately
2 weeks, before early frozen stocks were prepared. For mouse reinjec-
tion, fresh cells at passage 2 were used. For the other experiments, in-
cluding proliferation, invasion, neurosphere formation, and Western
blot analysis, cells derived from the early stocks after one or two addi-
tional passages were used.
Histology and Immunostaining
Brains were embedded in paraffin, and 4-μm sections were processed
for hematoxylin and eosin (H&E) staining or immunohistochemistry
(IHC) as previously described [10,11]. For IHC, the primary anti-
bodies GFP, phospho-Erk (P-Erk), and phospho-Akt (S473) were
used at 1:300 dilution (see also below for antibody information).
Immunofluorescence analysis was performed as described [12]. Image
stacks were acquired with a Zeiss Axiovert 200M inverted micro-
scope and deconvolved with the AxioVision Rel 4.5 SP1 software (Carl
Zeiss MicroImaging).
Invasion Assays
To assess cell invasiveness, a new three-dimensional invasion assay
was used, which uses a method for levitated cell culturing where
cells grown in monolayer cultures at 80% confluence are treated with
1 μl of hydrogel per 1 cm2 of surface area [13,14]. As a represen-
tation of the normal brain parenchyma, we used NHAs stably ex-
pressing mCherry. NHA-mCherry and Inv-GFP or Core-GFP cells
pretreated with hydrogel were detached by treating with trypsin-
EDTA and placed into a new tissue culture Petri dish containing
DMEM–10% FBS. A top with an attached neodymium magnet cov-
ered the dish to induce levitation and formation of three-dimensional
spheres of gel-treated cells in 3 to 5 days. Once structures of similar
sizes were achieved, an NHA-mCherry sphere was placed in the same
dish with either an Inv-GFP or Core-GFP sphere, while the neo-
dymium magnet on the cover brought structures together. The
subsequent infiltration of the GBM-GFP cells among the NHA-
mCherry cells was recorded with a Zeiss Axiovert 200M inverted
microscope, and images were deconvolved with the AxioVision Rel
4.5 SP1 software. For the Matrigel invasion assay, 1 × 106 cells were
prepared in duplicate in 250 μl of serum-free DMEM. The cells
were placed in transwells with 8-μm pore size polycarbonate filters
(Corning Incorporated, Corning, NY), precoated with 100 μl of
0.7 mg/ml Matrigel (BD Biosciences). The lower wells were filled
with 750 μl of DMEM. The cells were incubated at 37°C for
24 hours, fixed with methanol, and stained with H&E. Nonmigra-
tory cells on the upper surface of the transwells were removed with a
cotton swab, and the migratory cells from the lower surface of the
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transwell were solubilized in 500 μl of 2% (wt./vol.) sodium dodecyl
sulfate solution. The intensity of the dye was quantified by measur-
ing the absorbance at 620 nm with a Beckman spectrophotometer
DU640 (Beckman Coulter, Brea, CA).
Proliferation and Apoptosis
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT; Sigma-Aldrich, St Louis, MO) assay was used to measure pro-
liferation, as described [15]. For the apoptosis assay, 5000 cells were
plated on eight-chamber slides and allowed to attach overnight. Once
attached, cells were treated with rapamycin (100 nM/ml) for 72 hours.
Apoptosis detection was performed with the In Situ Cell Death De-
tection Kit, TMR Red (New England Biolabs, Ipswich, MA), as spec-
ified by the manufacturer (Figure W2).
Neurosphere Formation and Renewal Assays
A total of 104 U251-MG parental, Inv, and Core cells were seeded
in triplicates in 60-mm low-binding dishes containing 6 ml of neuro-
sphere growth medium (DMEM F12, B27, 20 ng/ml epidermal
growth factor, and 20 ng/ml basic fibroblast growth factor) and were
allowed to grow for 2 weeks/passage. The growth factors were replen-
ished every 7 days. For the renewal assay, six individual neurospheres
of similar sizes were separated into microcentrifuge tubes, washed
once with PBS, incubated in 0.25% trypsin-EDTA for 10 minutes
at 37°C, and then homogenized and returned to the neurosphere
growth medium. For quantification, 10 aliquots of 100 μl each were
taken from each neurosphere dish and plated separately into 10 wells
of a 96-well plate. Bright field images of each well were acquired, and
the average number of neurospheres was calculated. The average
neurosphere area size was measured with the ImageJ software (NIH,
Bethesda, MD).
Protein Analysis and Antibodies
The protocols for cell lysis and Western blot analysis were previ-
ously described [12]. Antibodies used include the following: Erk1
(C-16, rabbit polyclonal), Erk2 (C-14, rabbit polyclonal), and glyceral-
dehyde 3-phosphate dehydrogenase (sc-47724, mouse monoclonal)
from Santa Cruz Biotechnology (Santa Cruz, CA); phospho-Ser473-
Akt (rabbit polyclonal), Akt/protein kinase B (rabbit polyclonal), and
phospho-p44-p42-T202/Y204-MAP kinase (P-Erk, mouse mono-
clonal) from Cell Signaling (Danvers, MA); PH domain leucine-rich
repeat protein phosphatases 1 and 2 (PHLPP1 and PHLPP2; rabbit poly-
clonal) from Bethyl Laboratories (Montgomery, TX); CD133 (rabbit
polyclonal) from Abcam (Cambridge, MA); β-tubulin (mouse mono-
clonal) from Sigma; andGFP (mouse monoclonal), nestin (mouse mono-
clonal), glial fibrillary acidic protein (GFAP; rabbit polyclonal), and
actin (mouse monoclonal) from Chemicon/Millipore (Billerica, MA).
Results
In Vivo Selected Human GBM Cells Induce Invasive Tumors
in SCID Mice Resembling Human Disease
Human GBM cells lines have been widely used in mouse xeno-
graft models, especially the highly tumorigenic but noninvasive cell
line U87-MG [16]. In this study, we tested the tumorigenicity in
immunodeficient animals of an array of GBM cell lines (not shown),
and we used the weakly tumorigenic cell line U251-MG to analyze
the molecular mechanisms of in vivo tumor dispersal. For tracking,
parental cells were engineered to stably express GFP, this did not
change the phenotypic characteristics of the cells (Figure W1). The
moderate tumorigenicity of our stock of U251-MG cells proved op-
timal for this study because longer mouse survival allowed time for
infiltration of the brain with invasive cells (Figure 1). SCID mice in-
tracranially injected with U251-GFP–labeled cells demonstrated a
biphasic survival pattern extending for 40 weeks (Figure 1A). Surpris-
ingly, two distinct histopathological variants were observed in tumors
isolated from these mice. With one exception, mice succumbing earlier
than 20weeks after inoculation developed tumors with parental-like cell
morphology. The longer-time survivors developed well-circumscribed
heterogeneous tumors with multinucleated giant cells (Figure 1, A
and B). The cells isolated from the tumor of the longest surviving ani-
mal (Figure 1A) maintained giant morphology and grew poorly in cul-
ture (Figure W2), correlating the culture findings with the slow growth
rate of these tumors in mice.
To isolate the cells that infiltrated the brain, the brain quadrant con-
taining the primary tumor developing at the injection site was dissected
from the rest of the brain (Figure 1C). In the dissected material, foci
of GFP-labeled tumor cells were visualized at the injection site and
in the opposite hemisphere, and paired cultures of GFP-expressing
cells were obtained from each dissected brain (Figure 1D). Cells iso-
lated from the primary tumor were labeled as Core, and invasive cells
isolated from the remaining three quadrants were labeled as Inv.
To analyze the tumorigenic characteristics of the Core and Inv cells,
three distinct pairs of cells obtained from the first three short-term sur-
viving mice (Figure 1A) were reinjected into SCID mice. Surprisingly,
Inv cells uniformly killed the animals twice as fast as Core cells (Fig-
ure 2A). Paraffin sections were prepared from dissected brains and
examined for tumor cell infiltration. The Core cells formed large bulky
tumors that detached in some places from the brain on sectioning
(Figure 2, B and C , arrow). In contrast, the Inv cells did not grow
as bulky tumors but massively infiltrated the ependyma, neuropil,
and meninges, including the space between the caudal cerebrum
and the cerebellum (Figure 2B, arrows). Marked dilatation of all ven-
tricles was observed in mice inoculated with Inv cells, most likely ac-
counting for the accelerated course of the neurological disease in these
animals. The Core cells also appeared to invade in ball-like structures
in the proximity of the main tumor mass, but Inv cells traveled at long
distances in small clusters encircling blood vessels, a phenomenon
known as satellitosis (Figure 2C).
To characterize the patterns of migration and confirm the identity
of the Inv infiltrating cells, we performed immunostaining with GFP
antibody that labels GFP-expressing tumor cells. Several patterns of
migration encountered in human GBM [17,18] were identified in
mice inoculated with Inv cells (Figure 2D), indicating similitude be-
tween this mouse model and human GBM.
In Vitro Testing of In Vivo–Selected Invasive GBM Cells
Reveal Increased Invasion and Decreased Proliferation
The invasive capacity of the Inv and Core cells was tested in vitro in
a new three-dimensional invasion assay on the basis of magnetic levi-
tation that allows infiltration of NHAs by GBM cells (Figure 3A) [13].
Individual three-dimensional structures of Inv-GFP and Core-GFP
cells were brought in contact with NHA-mCherry by the magnetic
field (Figure 3B). After contact was established, the three-dimensional
assemblies were imaged at different time points (Figure 3C ). Whereas
the edge of the Core cell spheres remained intact and only very few
cells escaped and invaded into the astrocyte structure (Figure 3C , right
panel, dotted contour and arrows), the edge of Inv cell spheres breached,
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and most peripheral cells extensively penetrated between the NHAs
(Figure 3C , left panel, dotted contour). A conventional Matrigel inva-
sion transwell assay was also performed with these cells and showed
a small enhancement of the invasive ability of Inv cells compared
with Core or parental cells (Figure 3D). Taken together, these experi-
ments show that Inv cells demonstrated enhanced invasiveness in vitro,
both by infiltrating NHA cells, as shown in the three-dimensional
magnetic levitation assay, and by invading the ECM, as shown in
the Matrigel assay.
In contrast to the increased invasiveness, the proliferation rate of
Inv cells was significantly reduced compared with Core cells (Fig-
ure 3E ). U251 parental cells had an intermediate proliferation rate.
Altogether, these experiments showed increased invasiveness and de-
creased proliferation for Inv cells versus Core cells.
Figure 1. Isolation of invasive (Inv) GBM cells in vivo. (A) Kaplan-Meier survival curve of SCID mice (n = 9) inoculated intracranially with
GFP-labeled parental U251-MG cells. The biphasic mouse survival pattern segregates tumor morphology into parental (P)-like (survival <
20 weeks) or giant cell (survival > 20 weeks) except for animal 8* that developed P-like tumor. On the right, the processing route of the
isolated brains is indicated. (B) H&E staining showing the two tumor morphologies identified from the animals circled in (A). The IHC with
anti-GFP antibody confirms the U251 origin of the giant multinucleated cells. (C) Procedure scheme: the upper panel depicts a mouse
brain and the site of injection of GFP-labeled parental cells (red square). The right front quadrant containing the core of the tumor (right
panel) and the remaining three quadrants containing invasive cells (left panel) were processed separately for isolation of pairs of Core
and Inv cells, respectively. (D) Fluorescent visualization of the two GFP-labeled cell populations growing in situ, in the brain of mice
(upper panels), and after isolation in culture (lower panels).
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In Vivo–Selected Invasive GBM Cells Acquire Stem
Cells Characteristics
When comparing Inv to Core cells, it becomes apparent that the
in vitro proliferation phenotype did not correlate with the in vivo tu-
morigenesis. Another possibility for Inv cells to be more tumorigenic
would be that a higher number of cells within the population have
stem cell properties inducing more tumor foci in mice. We first an-
alyzed the expression of nestin and CD133, as markers for neural
stem cells, and of GFAP, as a marker of astrocytic differentiation.
Nestin was upregulated in Inv cells compared with both parental
and Core cells, and GFAP was upregulated in Core cells (Figure 4,
A and B). CD133 was upregulated in both in vivo–derived populations
compared with parental cells (Figure 4B), suggesting that, although
both populations acquired stem cell markers, Inv cells appeared less
differentiated than Core cells.
A property of stem cells is the long-term self-renewal or “stem-
ness.” Tumor stem cells derived from GBM can form and be prop-
agated as neurospheres when grown in suspension [19]. When we
analyzed the neurosphere-forming ability at the first passage of sus-
pended cells, equal numbers of neurospheres resulted from parental,
Inv, or Core cells (Figure 4C , upper row). Core cells formed much
larger neurospheres, compared with the others, most likely because
of their enhanced proliferation rate. When we propagated the cells
for neurosphere renewal, Inv cells formed a higher number of neuro-
spheres than Core cells, whereas parental cells were unable to renew
neurospheres at all (Figure 4C , lower row). Renewal Core neurospheres
Figure 2. Inv cells are more tumorigenic in vivo than Core cells. (A) Survival of mice inoculated with the three pairs of Core and Inv cells
isolated from the brains of the mice 1, 2, and 3 shown in Figure 1A. Survival periods are expressed as individual values distributed
around the mean. (B) H&E showing gross morphology of the brain (original magnification, ×25). Note infiltration with Inv cells of epen-
dyma and meninges (arrows) with marked dilatation of the third ventricle. Note also bulky detached tumors (arrow) of Core cells without
infiltration of the ventricles (left panel). (C) H&E showing infiltration of the brain parenchyma by cells detached from the main tumor mass
in mice inoculated with either Core or Inv cells. Arrows indicate the main tumor mass; arrowheads, the infiltrative cells. (D) Patterns of
migration of Inv cells in the brain of mice. IHC with GFP antibody distinguishes the tumor cells from the normal parenchyma. Arrows
indicate the tumor mass; arrowheads, infiltrative cells. Note several patterns of migration: in clusters surrounding blood vessels (satel-
litosis), in the white matter (1 and 5), the gray matter (2), or in the white matter tracts (3); migration as separate cells (4 and 5); and
migration as trains of cells along the white matter tracts (6).
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were still larger than Inv neurospheres, although the size difference
dropped from 2.5-fold for the first passage to 1.6-fold for renewal
neurospheres (Figure 4C , graphs). As for the cultured cells, renewal
Inv neurospheres showed a higher expression of nestin, whereas Core
neurospheres showed a higher expression of GFAP that was mainly
distributed at the periphery of the structures (Figure 4D).
Another property of stemlike cells is their relative resistance to
drug treatment. We tested the response of cells to rapamycin treat-
ment and observed that whereas approximately 40% of parental cells
underwent apoptosis, Core cells had only 2.6% apoptotic cells and
virtually no apoptosis occurred in rapamycin-treated Inv samples (Fig-
ures 4E and W3, A and B). Rapamycin inhibits the mammalian target
of rapamycin complex 1 (mTORC1), and we confirmed that it ef-
fectively suppressed the phosphorylation of p70S6K, a downstream
mTORC1 target (Figure W3C). Paradoxically, it increased Akt-Ser473
phosphorylation in all three populations, most likely by release of
an mTORC1-inhibitory feedback loop on PI3K/Akt signaling [20].
It seems that, overall, Inv cells showed a more pronounced phenotype
consistent with stem cell behavior than Core cells, explaining most likely
the increased oncogenicity of Inv cells in vivo.
Opposite Activation of Erk and PI3K/Akt Pathways in
Invasive Versus Noninvasive GBM Cells
To address the mechanism of the observed phenotypes in Inv and
Core cells, we investigated a series of pathways and molecules involved
in proliferation and invasion. Of these, Erk activation was systematically
Figure 3. In vivo–selected Inv cells demonstrate increased invasion and decreased proliferation relative to Core cells. (A) Three-dimensional
in vitro invasion assay setup: the GBM or NHA cells treated with Au-Phage-FeO (Levitated 3D Cell Culture) were held in suspension by
the magnetic field of a magnet attached to the top of the tissue culture plate (Magnetic Drive). (B) Three-dimensional spheres were allowed
to form separately from GFP-labeled Inv and Core cells and from mCherry-labeled NHAs and magnetically guided together. (C) Serial fluo-
rescence images for 48 hours of GBM-NHA composites show an invading front of Inv cells at the contact area with NHAs (dotted line)
in contrast to the unaltered surface maintained by Core cells in contact with NHAs. (D) Matrigel invasion assay showing increased invasion
of Inv cells compared with parental (Par) or Core cells. (E) MTT proliferation assay of U251-MG parental, Inv, and Core cells shows higher
proliferation of Core cells. Data are means ± SEM from triplicates. P values were computed by using paired t test. These experiments
were repeated three times with similar results.
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altered in three distinct pairs of Inv/Core cells (Figure 5A). Erk phos-
phorylation (activation) was upregulated in Core cells and down-
regulated in Inv cells compared with parental cells (Figure 5A),
and these differences correlated well with the higher or lower in vitro
proliferation rates of Core and Inv cells, respectively. To exclude the
potentially confounding effects of cell culture, we also performed
IHC with phospho-Erk antibody on tumor tissue sections from mice
injected with Inv or Core cells. A striking difference not only in
phospho-Erk expression but also in subcellular localization was ap-
parent: Core-derived tumors presented very high levels especially in
the nuclei of tumor cells, whereas Inv-derived tumors had low cyto-
plasmic levels. The high nuclear expression of phospho-Erk in Core
Figure 4. Invasive cells show stem cell characteristics. (A) Immunofluorescence with nestin antibody shows increased staining in Inv
cells. (B) Immunoblot analysis with indicated antibodies of protein extracts from U251-MG parental (Par), Inv, and Core cells shows
increased GFAP expression in Core cells and gain of CD133 expression in both subpopulations. (C) Bright field images (original mag-
nification, ×200) of passage 1 (upper row) and renewal (lower row) parental, Inv, and Core cell neurospheres. The graphs show the
number of spheres in green squares and the sphere size in red bars. Data are means ± SEM from counts of 10 wells. These experiments
were repeated three times with similar results. (D) Immunofluorescence with indicated antibodies of Inv and Core renewal neuro-
spheres. Note increased expression of GFAP in Core neurospheres and of nestin in Inv neurospheres. (E) TUNEL apoptosis assay of
rapamycin-treated parental, Inv, and Core cells. Data are means ± SEM from quadruplicates. These experiments were repeated three
times with similar results.
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tumors strongly suggested that Erk might drive the high proliferation of
Core cells leading to the development of bulky tumors in these mice.
Conversely, Akt phosphorylation on Ser473 that reflects its activa-
tion was higher in Inv cells than in Core cells, with statistically sig-
nificant differences in two Inv/Core cell pairs (Figure 5C ). In this
case, the activation of the PI3K/Akt pathway appears important for
the higher invasiveness, stemness, and in vivo tumorigenicity of Inv
versus Core cells. IHC of tumor tissue sections with phospho-Akt
Ser473 antibody showed a moderate cytoplasmic expression in cells
from Inv-derived tumors and absent staining in Core-derived tumors
(Figure 5D). Overall, phospho-Akt was increased in Inv cells versus
Core cells but seemed to have similar levels in Inv and parental U251
cells (Figure 5C ). The major suppressor of the PI3K/Akt pathway is
the PTEN tumor suppressor [21]. In U251 cells, PTEN is inac-
tivated by mutation [22], was absent in all three cell populations
(not shown), and, therefore, is not a candidate for the observed Akt
changes. Recently, PHLPP1 and PHLPP2 have been shown to specif-
ically dephosphorylate Akt phospho-Ser473 and suppress Akt activity
[23,24]. Examination of the expression levels of PHLPP1 and
PHLPP2 in parental, Inv, and Core cells showed a drop of PHLPP1
in Inv cells, which could explain the increase of phosphorylated Akt
in these cells in comparison to Core cells (Figure 5E). The levels of
PHLPP2 correlated with the levels of phospho-Akt in the three popu-
lations, the lowest being in parental cells and the highest in Core cells
(Figure 5E , graph). Overall, Core cells had high levels of both
PHLPP1 and PHLPP2, most likely responsible for the very low levels
of phospho-Akt in these cells.
Discussion
GBM is a rapidly lethal condition because of the existence of dispersed
tumor cells at distant sites within the brain at the time of the surgical
resection of the primary tumor. We aimed to reproduce the human
condition and characterize the infiltrative GBM cells. We therefore in-
oculated intracranially a cohort of immunodeficient mice with human
GBM cells of low tumorigenic potential to allow for dispersal of the
tumor cells before the mice die due to the mass effect of the primary
Figure 5. Erk and Akt are differentially activated in Inv versus Core cells. (A) Western blot analysis of phosphorylated P-Erk in three pairs
of Core and Inv cells derived from three mice (Figure 1A). P-Erk levels were normalized to total Erk1 (P-Erk/Erk), and results were rep-
resented as means ± SEM from two experiments. The panels show results from Pair #1 compared to parental (Par) cells. The percent-
age P-Erk/Erk activation (act.) is indicated under the corresponding bands. (B) IHC with P-Erk antibody of tumor sections from mice
injected with Inv and Core cells showing high nuclear P-Erk levels in Core tumor cells. (C) Western blot with P-Akt (Ser473) antibody
and analysis of P-Akt/Akt activation in the three sets of Inv/Core cells as in panel A. (D) IHC with P-Akt antibody of Inv and Core tumor
tissue sections showing higher P-Akt cytoplasmic levels in Inv tumor cells. (E) PHLPP1 and PHLPP2 levels in parental, Inv, and Core cells.
The graph represents PHLPP1 and PHLPP2 levels normalized to actin.
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tumor. Interestingly, during the 3- to 9-month survival interval, two
tumor pathologies developed, one with cells resembling parental U251
cells and one with giant multinucleated cells. The latter appeared only
in mice surviving more than 5 months after injection and closely re-
sembled the giant cell GBM subtype in humans that, despite its highly
atypical histological appearance, has better prognosis [25]. This is the
first report of a xenograft model of this tumor subtype, and a relatively
benign proliferation and migration phenotype correlating with the
phospho-Erk and phospho-Akt levels, respectively, was confirmed in
these cells (Figure W4).
We studied more in detail the dispersal of GBM cells in the brain
of mice with tumors of parental cell morphology that, in general, de-
veloped more rapidly than the giant cell tumors. Isolation of primary
tumor Core cells and of invasive Inv cells allowed matched compar-
ison of cells grown in vivo in the same conditions. Surprisingly, Inv
cells showed a significantly more aggressive phenotype than Core
cells when reimplanted in mouse brains, suggestive of the aggressive-
ness of GBM recurrences in patients. These findings are different
from previous studies with human xenografted GBM cells showing
an increase in tumorigenicity with decreasing invasive potential of
the xenografts [26,27]. However, the difference may come from
the different strategies used for obtaining the human GBM xenograft
model. Whereas we compared matched Core and Inv cell popula-
tions derived from the same animal, these studies compared tumor
core cells derived from early animal passages with those from late pas-
sages. In our case, both groups of in vivo–selected cells were strongly
tumorigenic, and no further increase in tumorigenicity was observed
on two additional rounds of intracranial inoculations of Inv cells (not
shown). This showed that during the first passage in the mouse
brain, the initial low-oncogenic parental GBM cells acquired their
full tumorigenic potential.
After examining several phenotypical properties, we concluded
that the main characteristic that differentiated the in vivo–selected
cell populations from parental cells was the acquired stemness by
in vivo growth (Figure 6). In particular, the in vivo–selected cells
could be propagated as neurospheres, whereas parental cells could
not, most likely because of anoikis. More importantly, the in vivo–
selected cells also became resistant to the apoptotic death that was
induced in parental cells by rapamycin treatment. These features that
define stem cells [28] were obviously acquired by parental cells dur-
ing in vivo growth but not during the growth within the first-passage
neurospheres, implicating the brain microenvironment as responsible
for promoting and maintaining these cells in a stem cell–like state
[29]. We believe that the parental U251 cells contain a mixture of
cells with different properties, including a subpopulation of stemlike
cells. This assumption is supported not only by a recent study report-
ing that U251 cells have a higher percentage of CD133 and nestin-
positive cells than other GBM cell lines [30] but also by our in vitro
cell cloning experiments that identified cell clones with higher or lower
Akt activation (not shown). Another argument supporting the exis-
tence of different cell subsets in the initial cell population is the devel-
opment of slowly growing giant cell tumors in half of the injected
mice, most likely deriving from a subset of slowly growing cells present
in the parental population. A parallel could be drawn between the
Figure 6. Model of GBM cell invasion. The initial parental population is most likely a mixture of different cell subsets, including putative
giant cell precursors giving rise to the giant cell tumors from Figure 1. The cells giving rise to the parental-like (P-like) tumors interact with
the brain microenvironment that enriches their stem cell–like state. The resulting Core and Inv cells may also contain different propor-
tions of two cell types: cancer stem cells (expressing nestin) and cancer cells (expressing GFAP). These different proportions would
confer the Inv and Core cells their phenotype and signaling signatures.
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growth of tumor variants from an initial mixed cell pool and the in-
fection of the host with a mixture of microorganisms. In our studies
with mixed viral poliovirus strains of different neuropathogenicities,
individual mice were affected randomly by the virus variants from
the mixture [31], suggesting an initial stochastic selection in the brain.
In the case of tumor cells, the different cell subsets injected would in-
teract with the brain microenvironment and differentiate into different
output populations (Figure 6). These output populations may be very
obviously different from the parental population, as in the case of the
giant cells or, more similar to this, as in the case of the Inv and Core
cells. The fact that the brain microenvironment can select populations
more and more adapted to it has been previously shown [26,27,32].
These differences may be gradually lost once the cells are removed
from the metabolic environment of the brain and placed in traditional
cell culture media. Therefore, the migratory phenotype in which we
are interested would be partly predetermined, resulting most likely
from two processes: a certain preexistent affinity of a cell subpopula-
tion for the ECM and a cross talk between these prespecialized cells
and the brain microenvironment.
Increased invasiveness was recently correlated to stem cell prop-
erties in various types of cells, including GBM cells that generate
invasive tumors [33]. We also observed that Inv cells have a more
pronounced stem cell appearance than Core cells, manifested by
higher nestin expression, self-renewal ability, and drug-induced re-
sistance to apoptosis. In our case, these characteristics directly cor-
related with increased in vivo and in vitro invasiveness. The higher
in vivo tumorigenicity of Inv cells versus Core cells contrasted with
their in vitro proliferation rate either in the two-dimensional culture
or in the three-dimensional neurospheres. However, this finding is in
agreement with a previous study with in vitro–selected invasive GBM
cells in which proliferation markers were downregulated [34] and
with the notion that cells with stemlike characteristics have a lower
proliferation rate than transit-amplifying cells [35]. It seems that the
Inv cells behave as cancer cells with stemlike characteristics, in that
they proliferate less, but once established at secondary sites, they up-
regulate their self-renewal and regrow tumors.
In a large screen with phosphoantibodies, we found that Erk is
significantly suppressed in Inv cells and activated in Core cells. In
contrast, Akt was activated in Inv cells and inhibited in Core cells.
Both of these pathways have been implicated in cell invasion, pro-
liferation, and differentiation, and the PI3K/Akt pathway has also
been firmly implicated in the maintenance and self-renewal of plurip-
otent embryonic stem cells [36]. Whereas it is known that cytokines,
growth factors, and ECM components stimulate both pathways simul-
taneously, an inhibitory cross talk between the PI3K/Akt and Raf/
MEK/Erk pathways has been characterized, and it relies on the sup-
pression of Raf kinase activity through phosphorylation of a conserved
residue in the regulatory domain by Akt [37]. Interestingly, this inhi-
bition is triggered only by a strong stimulation of the PI3K/Akt path-
way and not by stimuli that preferentially activate the Erk pathway
[38]. It is important to note that the PI3K/Akt pathway in U251 pa-
rental cells is already strongly activated by PTEN deficiency [39] and
that PTEN loss of heterozygosity is a frequent event in GBM [1]. It
is thus tempting to speculate that the tuning of the PI3K/Akt path-
way, most likely by local growth factors and ECM components from
the brain microenvironment, regulates in turn the Erk pathway and
the ability to invade or proliferate of the GBM cells. In the case of the
U251 xenograft, even if all the cells had PTEN deletion, a process
of selective spatial positioning most likely took place. Consistent with
our model discussed previously, the cells with lower Akt and higher
Erk activation underwent selection toward enhanced proliferation in
the core of the tumor, and the cells with high Akt and low Erk ac-
tivation actively invaded the surrounding parenchyma along blood
vessels and white matter tracts.
We identified that the activation of Akt was controlled in vivo by
the PHLPP phosphatases in the U251 PTEN-negative cells. In pa-
rental cells, the levels of PHLPP1 were relatively high, whereas those
of PHLPP2 were low. In the in vivo–selected cells, a switch of the
levels took place. Thus, in Inv cells, PHLPP1 was considerably re-
duced, and its low levels were maintained in invasive cells harvested
from mice after two in vivo passages of Inv cells (not shown). Con-
versely, in Core cells, PHLPP2 was increased, resulting in Akt suppres-
sion. We have recently shown that PTEN and PHLPP1 depletion
synergistically activate Akt in PTEN-positive GBM cells and that
the levels of both PHLPP1 and PHLPP2 inversely correlate with
Akt activation in PTEN-negative GBM cells (unpublished data). Here,
we found that the cells selected their PHLPP levels in vivo to adapt
the intensity of Akt activation to a proliferative or invasive phenotype.
In summary, we developed in this study a mouse orthotopic model
of human invasive GBM. The invasive cells presented stem cell char-
acteristics and increased tumorigenicity. We found high Akt and low
Erk activation in the invasive cells and a reversed pattern in the tu-
mor core cells. Because the GBM recurrences in patients arise from
invasive cells not removed by the initial surgical resection, these find-
ings prompt consideration of anti-PI3K/Akt inhibitors to target the
remaining invasive cells. If an inhibitory Akt-Erk cross talk is present
in invasive cells, an unwanted activation of the Erk pathway may
ensue from the PI3K/Akt inhibition, resulting in increased local pro-
liferation and recurrence. Therefore, future studies in our model will
address these drug escape mechanisms and test combination thera-
pies with inhibitors for both pathways.
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Figure W1. MTT proliferation assay of U251-MG cells either noninfected (U251) or infected with retroviruses carrying pCXp-GFP vector
for stable GFP expression (U251-GFP). Note no difference in proliferation induced by GFP expression.
Figure W2. Morphology of parental U251-MG cells and of the cells isolated from the animals 1 (Core and Inv) and 9 (giant) from
Figure 1A. Bright field images at an original magnification of ×400.
Figure W3. Resistance to apoptosis induced by rapamycin treatment of in vivo–selected Inv and Core cells. (A) Control TMR Red apop-
tosis assay showing 100% apoptosis by treatment with DNase I of parental U251-MG cells labeled with GFP. Apoptosis was recognized
by treating the fixed permeabilized cells with terminal deoxynucleotidyl transferase followed by treatment with TMR Red to label the
DNA strand breaks. Double-labeled nuclei appear yellow in the merged image. (B) Parental, Inv, and Core cells were treated with 100 nM
rapamycin for 72 hours and assayed for apoptosis. Four images were recorded per chamber in both green and red channels with a Zeiss
Axiovert 200M inverted microscope, and the number of red cells (apoptotic) was calculated from the total number of cells (green cells;
graph in Figure 4D). (C) Parental, Inv, and Core cells were treated with the indicated doses of rapamycin for 72 hours. Cells were lysed
and analyzed by immunoblot analysis with antibodies for P-p70S6K, a downstream target of mTORC1, and P-Akt (Ser473), target of
mTORC2. Note efficient inhibition of p70S6K phosphorylation by rapamycin treatment. In contrast, Akt phosphorylation was increased
in the same conditions. Note also higher basal Akt phosphorylation of Inv cells compared with Core cells.

Figure W4. Reduced signaling, proliferation, and invasion of giant cells in comparison to parental U251 cells. (A) Western blot analysis of
protein extracts from parental (Par) and giant cells with antibodies against phosphorylated Erk and Akt (S473) and control total Erk1 and
2 and Akt. (B) MTT assay of parental and giant cells showing proliferation during a 6-day period. (C) Matrigel invasion assay showing very
reduced invasion of giant cells compared with parental (Par) cells.
